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B V L Potter3, M J Reed1,{, A Purohit1,6 and P A Foster*,1,5,6
1Oncology Drug Discovery Group, Section of Investigative Medicine, Hammersmith Hospital, Imperial College London, London
W12 0NN, UK; 2Cancer Institute, UCL, 72 Huntley Street, London WC1E 6BT, UK; 3Medicinal Chemistry, Department of Pharmacy
and Pharmacology, University of Bath, Bath BA2 7AY, UK; 4Systems Biology, IPSEN, 5 Avenue du Canada, Les Ulis 91966, France
and 5Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of
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Background: STX2484 is a novel non-steroidal compound with potent anti-proliferative activity. These studies aimed to identify
STX2484’s mechanism of action, in vivo efficacy and activity in taxane-resistant breast cancer models.
Methods: Effects of STX2484 and paclitaxel on proliferation, cell cycle and apoptosis were assessed in vitro in drug-resistant
(MCF-7DOX) and non-resistant cells (MCF-7WT). STX2484 efficacy in bIII tubulin overexpression in MCF-7 cells was also determined.
Anti-angiogenic activity was quantified in vitro by a co-culture model and in vivo using a Matrigel plug assay. An MDA-MB-231
xenograft model was used to determine STX2484 efficacy in vivo.
Results: STX2484 is a tubulin disruptor, which induces p53 expression, Bcl2 phosphorylation, caspase-3 cleavage, cell cycle arrest
and apoptosis. In addition, STX2484 is a potent anti-angiogenic agent in vitro and in vivo. In breast cancer xenografts, STX2484
(20mgkg 1 p.o.) suppressed tumour growth by 84% after 35 days of daily dosing, with limited toxicity. In contrast to paclitaxel,
STX2484 efficacy was unchanged in two clinically relevant drug-resistant models.
Conclusions: STX2484 is an orally bioavailable microtubule-disrupting agent with in vivo anti-angiogenic activity and excellent
in vivo efficacy with no apparent toxicity. Crucially, STX2484 has superior efficacy to paclitaxel in models of clinical drug resistance.
Microtubule-targeting agents, such as the taxanes and Vinca
alkaloids, are widely used in the treatment of solid tumours,
including those of the ovary, prostate and breast, as they selectively
target rapidly dividing cells. However, their activity is offset by
dose-limiting side effects including neutropenia and neurotoxicity.
In addition, some of these drugs also provoke hypersensitivity
reactions triggered by the presence of non-ionic surfactant,
Cremophor EL, in the formulation. The toxic nature of these
compounds means that the optimal anti-tumour dose can only be
given intermittently, with a requirement for treatment holidays,
thus allowing time for tumour regrowth and drug resistance to
develop (Gelderblom et al, 2001; Ring and Ellis, 2005; Mielke et al,
2006).
Drug resistance is a major problem in the effective treatment of
breast cancer. Many patients have intrinsic resistance to the
taxanes, and even those that do initially respond will eventually
acquire resistance to this class of compounds, resulting in disease
progression. Clinically, resistance to microtubule-targeting agents
is most likely multi-faceted and can be mediated by overexpression
of P-glycoprotein, a drug efflux pump (Fojo and Menefee, 2005),
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overexpression of class III b-tubulin (Burkhart et al, 2001) and
tubulin post-translational modifications (Orr et al, 2003). Thus,
development of compounds that can hit multiple targets to
overcome these drug-resistant mechanisms is a key goal for new
drug development.
The current drive for targeted therapies is potentially masking the
real need for new cytotoxic agents, as to date all FDA approvals for
targeted therapy for breast cancer are in conjunction with/adjunct to
a traditional cytotoxic agent. Monotherapy with targeted agents has
had minimal effect on survival rates, and their addition to cytotoxic
regimes only has a marginal advantage (Normanno et al, 2009).
Therefore, there remains an unmet need to develop new cytotoxic
agents with an improved toxicity profile, better solubility and less
susceptibility to drug-resistant mechanisms to partner new targeted
agents. One such new drug class is the epothilones, which are potent
microtubule disruptors with efficacy in drug-resistant cell lines
in vitro (Hunt, 2009). The lead epothilone, Ixabepilone, has been
approved by the FDA for use in taxane-refractory metastatic breast
cancer (Cigler and Vahdat, 2008). However, this drug still requires a
Cremophor-based infusion and its approval in Europe is delayed
owing to concerns regarding the levels of neuropathy seen in the
clinical trials (Cavaletti, 2009). To overcome this problem, the
epithilone analogue, UTD1 was synthesised and showed better
results than the latter in the phase I clinical trial in solid tumours,
particularly in terms of myelosuppression (Zhang et al, 2011). A less
advanced class of compounds is the steroidal sulphamoylated
compounds; the lead compound, 2-methoxyoestradiol-3,17-O,O-bis-
sulphamate, is still in pre-clinical development but has shown potent
anti-cancer activities both in vitro and in vivo (Chander et al, 2007;
Raobaikady et al, 2005; Newman et al, 2008; Day et al, 2009;
Meyer-Losic et al, 2013).
We have previously synthesised a novel class of non-steroidal
compounds combining reduced toxicity, improved solubility, ease
of synthesis and activity in clinically relevant models of drug
resistance (Leese et al, 2010). Preliminary in vitro proliferation
assays have identified 2-(3,4,5-trimethoxybenzyl)-6-O-sulphamoyl-
7-methoxy-1,2,3,4-tetrahydroisoquinoline (STX2484) as a potential
pre-clinical lead for this class of compounds. Therefore, the aims of
this study were to identify the primary mechanism(s) of action of
this compound, to assess its in vivo efficacy in a breast cancer
xenograft model, and crucially, to look for activity in clinically
relevant drug-resistant models of breast cancer.
MATERIALS AND METHODS
Drug synthesis. STX2484 was synthesised as described (Leese
et al, 2010). The compound exhibited spectroscopic and analytical
data in accordance with its structure (Figure 1) and was pure, as
determined by high-performance liquid chromatography. This
compound was tested together with the known microtubule-
stabilising agent, paclitaxel (Sigma, Poole, UK).
Cell culture. Oestrogen receptor-positive (ERþ ve) human breast
cancer MCF-7 cells and ER-negative (ER ve) human breast
cancer MDA-MB-231 cells were obtained from the American Type
Culture Collection (LGC Promochem, Teddington, UK) and used
within 20 passages, but were not authenticated. MCF-7DOX cells
were kindly donated by Dr GL Scheffer (Department of Pathology,
Free University Hospital, Amsterdam, The Netherlands). Cells
were routinely cultured in RPMI 1640 medium supplemented with
10% (v/v) fetal calf serum, 2mM L-glutamine, 1% non-essential
amino acids and 0.075% sodium bicarbonate from Sigma. Human
umbilical vein endothelial cells (HUVECs) were obtained from
TCS Cellworks (Claydon, UK) and maintained in a large vessel of
endothelial medium supplemented with basic fibroblast growth
factor/heparin, epidermal growth factor and cortisol in the
presence of amphotericin/gentomycin (TCS Cellworks). All cells
were cultured at 37 1C under 5% CO2 in a humidified incubator.
HUVECs were used up to passage 10.
Cell proliferation. To ascertain IC50 values, 5000 cells, in their
appropriate growth medium, were added to each well of a 96-well
microtitre plate (BD Biosciences, Cowley, UK). Plates were
incubated for 4–5h at 37 1C in a 5% CO2 humidified atmosphere
before addition of compounds. All compounds were dissolved at
10 2 M in tetrahydrofuran (THF) and added to the cells with a final
concentration of 0.1% or less THF. As MCF-7 and MDA-MB-231
cells have a similar doubling time of about 30 h, these assays were
done in parallel and the cells were exposed to inhibitors for the same
time. Cells were grown in the absence or presence of the compounds
for 4 days after which, 10ml per well of Alamar Blue (Biosource,
Camarillo, CA, USA) was added and incubated for 2 h. Fluorescence
was quantified using a FluoStar Optima Plate reader (544 nm
excitation, 590 nm emission; BMG Labtech, Aylesbury, UK).
Tubulin polymerisation assay. The polymerisation of purified
bovine brain tubulin (99% purity) was monitored using the
Tubulin Polymerization Assay Kit from CytoDYNAMIX
(Screen 03, Cytoskeleton Inc., Denver, CO, USA; Shelanski et al,
1973; Lee and Timasheff, 1977). Briefly, tubulin polymerisation
driven by guanosine triphosphate (GTP) and paclitaxel was
monitored spectrophotometrically by the change in absorbance
at 350 nm. The absorbance was measured at 1-min intervals
for 60min using a Victor spectrophotometer (Perkin-Elmer,
Buckinghamshire, UK).
Tubulin-competitive-binding assay. The competitive-colchicine-
binding assay is based on a scintillation proximity assay technology
using bovine brain tubulin, which has been modified so that
random surface lysines contain a covalently linked, long-chain
biotin derivative (CytoDYNAMIX screen 15, Cytoskeleton Inc.).
Briefly, 10ml of each compound was added to a well of a 96-well
plate (Low PB CorningCostar, Amsterdam, The Netherlands).
Tritiated colchicine (100 ml; Perkin-Elmer; specific activity
70–80Cimmol 1) was added to 300 ml of tubulin-binding buffer
and then 10 ml was added in each well. Premix tubulin–biotin–
streptavidin scintillation proximity assay beads (180ml; 4.4mg
streptavidin yttrium silicate beads are mixed into 15ml buffer and
incubated on a slow 10 r.p.m. rotator at 4 1C for 30min; Amersham
Bioscience, Little Chalfont, Buckinghamshire, UK) were added to
each well for 3 h at 37 1C. The plates were then read on a
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Figure 1. Structures of STX2484 (A) and Paclitaxel (B).
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scintillation counter (Packard Instrument, Meriden, CT, USA;
Topcount Microplate Reader) and the percentage of inhibition was
calculated (Tahir et al, 2000).
Immunohistochemistry. MCF-7 and MDA-MB-231 cells grown
on poly-L-lysine-coated coverslips were treated with 0.1 mM
STX2484 or paclitaxel for 24 h. The cells were fixed by placing
them in methanol at  20 1C for 10min, and then in ice-cold
acetone for 30 s. The coverslips were rinsed and then rehydrated
with PBS. To visualise the microtubules, cells were incubated for
1 h with the FITC-conjugated anti-b-tubulin (clone DM1A, Sigma)
in PBS containing 1% BSA. Cells were washed twice with PBS, and
the nuclei were counterstained with Hoechst 33 342 at 1mgml 1
(Sigma). Coverslips were mounted on slides using the DePex
mounting medium (BDH Chemicals Ltd, Poole, UK), observed
using a Zeiss (Carl Zeiss Ltd, Welwyn Garden City, UK) inverted
microscope ( 200) and analysed with the Axiovision imaging
system (Imaging Associates, Bicester, UK).
Cell cycle analysis. Cells were seeded in T-25 flasks, incubated
until 60–70% confluence and exposed to compounds at 0.5mM for
24 h, 48 h and 72 h. Cells were harvested, washed with PBS, pooled
with the non-adherent cells and centrifuged for 5min at 600 g. The
cells were fixed in ice-cold 70% ethanol and stored at  20 1C for
48 h. After fixation, cells were suspended in 100 ml phosphate–
citrate buffer (0.19mol l 1 Na2HPO4 and 4mmol l
 1 citric acid
(both from Sigma)) and incubated for 30min at room temperature.
Cells were then resuspended in 1ml PBS (Lonza, Verviers,
Belgium) containing 10mgml 1 propidium iodide (Sigma) and
10 mgml 1 RNase A (Sigma). The propidium iodide-stained cell
samples were analysed with a flow cytometer (FACSCalibur,
Becton Dickinson, Oxford, UK) at 620 nm. Further DNA analysis
was performed using MultiCycle AV software (Innovative Cell
Technologies, San Diego, CA, USA).
Apoptosis analysis. Cells were seeded and treated as described for
the cell cycle analysis. Cells and washings were pelleted by
centrifugation at 600 g, washed twice with PBS and resuspended in
600 ml Annexin V-binding buffer (10mM HEPES pH 7.4, 140mM
NaCl and 2.5mM CaCl2). A 150-ml aliquot of the cell suspension
was stained with 5 ml of propidium iodide (Invitrogen, Carlsbad,
CA, USA) at 50 g l 1 and 4 ml of FITC-conjugated Annexin V
antibody (BD Biosciences, San Jose, CA, USA). The apoptotic
status of the cells was analysed using a FACSCalibur flow
cytometer (Becton Dickinson). Cells undergoing apoptosis were
defined as positive for Annexin V and negative for propidium
iodide staining.
Immunoblotting. Cells were seeded in T-25 flasks at B2.5 105
cells per flasks in 4ml of cell-specific media and exposed to
compounds at 0.5mM for 24 h, 48 h or 72 h. Protein was prepared
from treated cells using RIPA lysis buffer (Sigma) and quantified
using the Bradford protein assay with Bradford reagent (Sigma).
Equal amounts of protein were loaded in all wells (15 mg). Proteins
were separated by electrophoresis through a 4–12% NuPAGE
Bis-Tris gel (Invitrogen) and subsequently transferred to Hybond-P
membrane (GE Healthcare, Buckinghamshire, UK).
Detection was carried out using anti-human cyclin B1 (ref.
H433; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
phospho-Bcl2 (ref. 2827S; Cell Signaling Technology, Boston, MA,
USA), caspase-3 (ref. 9665; Cell Signaling), GAPDH (ref. 2118; Cell
Signaling) and p53 (ref. ab28-100; Abcam, Cambridge, UK)
primary antibodies. Secondary alkaline phosphatase-conjugated
anti-rabbit IgG (ref. 7054; Cell Signaling) or anti-mouse IgG (ref
7056; Cell Signaling) antibodies were used for detection in
conjunction with a chemifluorescent substrate (ECF substrate,
ref. RPN5785; GE Healthcare). Bands were visualised and
quantified using a Storm imaging system (GE Healthcare).
In vitro angiogenesis assay. The effect of STX2484 on in vitro
vessel formation was assessed using an angiogenesis kit (TCS
Cellworks). For this assay, endothelial cells were cultured in a
24-well plate within a matrix of human diploid fibroblasts of
dermal origin in an optimised medium supplied by TCS Cellworks.
The co-cultured cells were incubated throughout the experiment at
37 1C under 5% CO2 in a humidified incubator. On day 1, the
culture medium was removed and replaced with medium contain-
ing STX2484 at concentrations between 10 nM and 0.5mM, and
VEGF at 2 ngml 1 (TCS Cellworks). On days 4, 7 and 9, the
medium was replaced with fresh medium containing STX2484 and
VEGF. On day 11, the cells were washed with PBS and fixed with
1ml 70% ethanol for 30min. After fixation, the cells were washed
with blocking buffer (1% BSA in PBS) and stained for CD31 in
accordance with the manufacturer’s instruction (TCS Cellworks).
The extent of vessel formation was then quantified using a high-
resolution transmissive scanner (ScanMaker 9800, Microtek,
Willich, Germany) as previously described (Newman et al, 2007).
In vivo angiogenesis assay. The anti-angiogenic potential of
STX2484 was assessed using a modified Matrigel plug assay as
previously described (Passaniti et al, 1992; Prewett et al, 1999;
Chander et al, 2007). All experiments were carried out under
conditions that complied with institutional guidelines. Female
C57BL/6J mice (Harlan, Bicester, UK) were anaesthetised, placed
on a heated pad (37 1C) and 0.5ml of ice-cold Matrigel (BD
Biosciences), supplemented with 500 ng of basic fibroblast growth
factor (bFGF; R&D Systems, Oxford, UK), and injected sub-
cutaneously into one flank of each mouse. Control mice received
Matrigel without bFGF. Twenty-four hours after Matrigel injection
the mice were divided into four treatment groups (n¼ 5): vehicle
(10% THF and 90% propylene glycol), bFGFþ vehicle, bFGFþ
STX2484 (20mg kg-1 p.o.) and bFGFþ STX2484 (60mg kg 1
p.o.), and animals were dosed consecutively for 4 days.
Quantification of the blood vessels within the Matrigel plugs was
facilitated through the i.v. injection of 100 ml of 0.25mgml 1
FITC-dextran (125 000 molecular weight; Sigma) 7 days after the
Matrigel injection. The animals were culled 20min after the FITC-
dextran injection and Matrigel plugs were removed and photo-
graphed before being dissolved in 1ml Dispase reagent (BD
Biosciences) for 16 h at 37 1C. The resulting solution was
centrifuged at 15 700 g at 20 1C for 30 s. The fluorescence of the
supernatant was measured using a Fluostar Optima plate reader
(BMG Labtech). The excitation and emission wavelengths were
480 nm and 520 nm, respectively. The fluorescence of the
samples was quantitated using a standard curve of FITC-dextran
(0.4–25 mgml 1).
Xenograft models. Athymic female MF-1 nude mice (nu–/nu–)
were purchased from Harlan at 5 weeks of age (B20–25 g in
weight). All experiments were carried out under conditions that
complied with UK Home Office Animals (Scientific Procedures)
Act 1986 and institutional guidelines. MDA-MB-231 cells (2 106)
were inoculated subcutaneously into one flank of each animal.
When tumours reached 100–150mm3, mice were randomly
divided into two treatment groups (n¼ 6): vehicle (10% THF
and 90% propylene glycol) or STX2484 (20mg kg 1). All
compounds were given orally, daily for 35 days. Throughout the
study, mice were weighed and tumour measurements were taken
on a weekly basis. Tumour volumes were calculated using the
formula; volume¼ lengthwidth2/2. For ethical reasons, animals
were removed from the study if tumour mean diameter exceeded
1.5 cm, as recommended by Workman et al (2010).
Statistics. In vitro experiments were carried out in triplicate and
data presented are representative of one of three such experiments.
Unless specified, all errors shown are the mean±s.d. Student’s
t-test was used to assess significance.
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RESULTS
Efficacy in drug-resistant models. STX2484 is a potent inhibitor
of proliferation in both ER ve and ERþ ve breast cancer cell
lines, with IC50 values of 0.27 mM and 0.16 mM in MCF-7WT and
MDA-MB-231 cells, respectively (Table 1). In MCF-7DOX cells,
which overexpress P-glycoprotein, STX2484 inhibited proliferation
with an IC50 of 0.45 mM, which is not significantly different to the
IC50 in MCF-7WT cells (P40.05; Table 1). The resistance factor,
which reflects the fold increase in the drug-resistant cell line
compared with the parental wild type, has previously been shown
to be 1000 for paclitaxel in MCF-7DOX cells (Newman et al, 2007).
The efficacy of STX2484 and paclitaxel was also determined in
cells under- or overexpressing class III b-tubulin (Stengel et al,
2010). Altering class III b-tubulin protein expression did not alter
the efficacy of STX2484 significantly (P40.05) in MCF-7 cells. In
contrast, MCF-7 cells overexpressing class III b-tubulin were
significantly less sensitive to paclitaxel, and the knockdown of class
III b-tubulin significantly increased their sensitivity to paclitaxel
(Po0.01; Table 1).
Microtubule disruption. Microtubule-destabilising agents, such
as colchicine, can inhibit GTP- and paclitaxel-stimulated tubulin
polymerisation in vitro, as measured by changes in turbidity
(MacCarthy-Morrogh et al, 2000). GTP and paclitaxel were used at
10 mM and mixed with STX2484. In this study, STX2484
significantly inhibited paclitaxel-stimulated tubulin polymerisation
(53% inhibition, Figure 2A) and GTP-stimulated tubulin poly-
merisation (37% inhibition, Figure 2A). It has been shown that that
drugs affecting tubulin polymerisation interact with tubulin either
at the taxane-binding, Vinca-binding or colchicine-binding sites.
The competition-binding scintillation proximity assay (Figure 2A)
shows that STX2484 competitively inhibited [3H]colchicine
binding on the purified brain bovine tubulin, suggesting that
STX2484 directly interacts with tubulin by binding to the
colchicine-binding domain. Used as negative controls, paclitaxel
was not able to displace labelled colchicine (data not shown).
Having demonstrated that STX2484 perturbs tubulin dynamics in
a cell-free model, its effect on cytoskeletal and nuclear morphology
were examined in vitro. MCF-7 and MDA-MB-231 cells were
exposed to 0.1 mM STX2484 for 24 h and subsequently processed
for immunofluorescence microscopy. STX2484 was used at a low
concentration compared with its IC50 values to observe STX2484
effect on the cytoskeleton without killing the cells. The exposure of
MCF-7 and MDA-MB-231 cells to STX2484 resulted in marked
effects on cell morphology and on microtubule structure.
Microtubules, which extended throughout the cytoplasm of control
cells (Figure 2B), had their integrity affected by STX2484 in both
cell lines. Cells were rounded and there was a visible loss of
microtubule structure in response to STX2484 treatment, with only
diffused microtubule staining visible around nuclei. Untreated cells
showed typical nuclear structures, whereas cells treated with
STX2484 displayed condensed and fragmented nuclei, which are
associated with apoptosis (Figure 2B).
Cell cycle/apoptosis. To further investigate the potential apoptotic
effects of STX2484, FACS analysis was undertaken. As STX2484
has efficacy in the MCF-7DOX P-glycoproteinþ ve cell line, this
was included in these experiments. STX2484 and paclitaxel were
used at the same dose for a direct comparison of efficacy in vitro.
The dose selected was 0.5mM, which is approximately the IC50
value of STX2484 in both MCF-7WT cells and MCF-7DOX cells, and
is 30-fold the IC50 value of paclitaxel in MCF-7WT cells; but this is
not a dose that significantly affects the proliferation of MCF-7DOX
cells (Newman et al, 2008).
The majority of untreated MCF-7WT cells (59.3%) were in the G1
phase, whereas those exposed to 0.5mM STX2484 or paclitaxel, 56.0%
and 77.4% cells, respectively, were arrested in the G2/M phase, and
only 13.7% (P¼ 0.004) and 5.7% (P¼ 0.022) cells were in the G1
phase, respectively, after 48 h treatment (Figure 3A). The number of
cells undergoing apoptosis was two-fold higher and 1.7-fold higher in
response to STX2484 and paclitaxel, respectively, compared with
untreated cells after 72 h (Figure 3B). In MCF-7DOX cells, paclitaxel
failed to induce G2/M arrest and apoptosis, whereas STX2484
arrested cells in G2/M (25.8% cells in the G1 phase and 59.3% cells in
the G2/M phase with P¼ 0.006 and P¼ 0.035, respectively,
compared with control) and induced a two-fold increase in the
number of cells undergoing apoptosis (Figures 3A and B).
Proteins associated with the cell cycle and apoptosis were
analysed to further investigate the mechanism of action of
STX2484 in both MCF-7WT and MCF-7DOX cells. Protein extracts
were prepared from MCF-7WT and MCF-7DOX cells treated with
0.5 mM STX2484 or 0.5 mM paclitaxel for 24, 48 and 72 h.
Cyclin B1 was only weakly expressed in untreated cells but was
strongly induced in MCF-7WT cells after 24 h treatment with either
STX2484 (15-fold vs MCF-7WT control) or paclitaxel (24-fold vs
MCF-7WT control). STX2484 also strongly induced cyclin B1 in
MCF-7DOX cells (12-fold vs MCF-7DOX control); in contrast, only a
limited induction was seen after 24 h treatment with paclitaxel
(five-fold vs MCF-7DOX control). Cyclin B1 protein expression
returned to baseline after 48 h in both cell lines (Figure 3C). In
MCF-7WT cells treated with either STX2484 or paclitaxel, p53
protein expression increased after 24 h (three-fold and five-fold vs
MCF-7WT control, respectively). In MCF-7DOX cells, STX2484
increased p53 expression but little increase was seen in response to
paclitaxel (three-fold and 1.5-fold, respectively, vs MCF-7DOX
control; Figure 3C). Phosphorylation of Bcl2 protein negates its
anti-apoptotic activity and allows apoptosis to occur via the
mitochondrial pathway. In this study, both STX2484 and paclitaxel
strongly induced the phosphorylation of Bcl2 in MCF-7WT cells
after 24 h (six-fold and 10-fold, respectively, vs MCF-7WT control),
but only STX2484 strongly induced Bcl2 phosphorylation in MCF-
7DOX cells (14-fold vs MCF-7DOX control; Figure 3C). Caspase-3,
which is activated by cleavage, has an important role in the
apoptotic response. Both STX2484 and paclitaxel induced caspase-
3 cleavage after 24 h treatment in MCF-7WT, but only STX2484
induces caspase-3 cleavage in MCF-7DOX (Figure 3C). To ensure
equal protein loading and successful transfer, the housekeeping
protein GAPDH was used as a loading control and its detection
showed steady expression.
Anti-angiogenic activity. As STX2484 is a potent inhibitor of
HUVEC proliferation (Table 1), its ability to inhibit angiogenesis
was assessed both in vitro and in vivo. In vitro, a co-culture model
was used in which endothelial cells are cultured with fibroblasts in
24-well plates. Representative high-resolution scans of the wells
show STX2484 completely and partially inhibited vessel formation
at 500 nM and 100 nM, respectively (Figure 4A). Quantification of
vessel formation revealed that STX2484 significantly inhibited
vessel formation by 92.4% at 500 nM (Po0.001), 20% at 100 nM
Table 1. IC50 values of STX2484 and paclitaxel in MCF-7WT, MDA-MB-
231, HUVEC and drug-resistant MCF-7 cells (n¼ 3/group)
Cell line STX2484 (lM) Paclitaxel (lM)
MDA-MB-231 0.16±0.02 0.0001±0.00002
MCF-7WT 0.27±0.03 0.001±0.00038
MCF-7DOX 0.45±0.07 410.0
MCF-7-TUBB3 0.14±0.03 45.0
MCF-7-siRNA-tubb3 0.18±0.02 0.0005±0.000062
HUVEC 0.17±0.01 0.001±0.00049
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(Po0.01), 20% at 50 nM (Po0.01) and 26% at 20 nM (Po0.01). No
significant effect was seen at 10 nM (Figure 4B).
The anti-angiogenic activity of STX2484 in vivo was tested in
mice using a Matrigel plug assay (Passaniti et al, 1992; Prewett
et al, 1999). The addition of bFGF (1 ngml 1) to the Matrigel
caused a marked increase in vascularisation, and quantification of
angiogenesis showed a two-fold (Po0.001) increase in fluores-
cence in response to bFGF (Figure 4C). Plugs removed from
animals dosed with STX2484 (20 or 60mg kg 1 p.o.) for 4 days
showed a marked reduction in the level of neovascularisation
compared with bFGF alone. The formation of new blood vessels
was significantly (Po0.001) inhibited by both 20mg kg 1 p.o. and
60mg kg 1 p.o. STX2484 compared with Matrigel plugs that
received bFGF in non-STX2484-dosed animals.
In vivo efficacy. An MDA-MB-231 breast cancer xenograft model
was used to assess the efficacy of STX2484 in vivo. Tumours in
untreated mice increased by B2400% in size (2429±329%,
Figure 5A) over 28 days, whereas dosing with STX2484
(20mg kg 1 p.o., daily) reduced tumour size by 84% compared
with control-treated (10% THF and 90% PG) mice at this time
point (413±166%; Po0.001; Figure 5A). Owing to large tumour
volumes, and to comply with published guidelines on animal
welfare in cancer research (Workman et al, 2010), all mice in the
control group were removed from the study after 28 days. After 35
days of treatment, xenograft volumes in STX2484-treated animals
were still suppressed. No significant weight loss was observed in
the STX2484-treated group, perhaps indicating a favourable
toxicological profile for this compound (Figure 5A inset).
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DISCUSSION
Microtubule-targeting agents are widely used in the clinic to treat a
variety of solid and haematological cancers (Jordan and Wilson,
2004). However, their efficacy is compromised by resistance
mechanisms, and their dosing is often limited by severe toxicity.
Therefore, there remains an unmet need for new therapies that are
active against treatment-refractory tumours and have a more
favourable toxicity profile. We demonstrate here one such
candidate, STX2484, a novel non-steroidal compound, which has
previously shown potent in vitro anti-proliferative activity in
preliminary screening assays.
The multiple methoxy groups and sulphamate group within the
structure of STX2484 strongly suggest that this compound may
interact with microtubules in a similar fashion to colchicine
and 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (Kumar 1981;
Newman et al, 2007). To investigate this, STX2484 was tested in
the paclitaxel-stimulated tubulin polymerisation assay, and like
both colchicine and 2-methoxyoestradiol-3,17-O,O-bis-sulpha-
mate, STX2484 blocked GTP- and paclitaxel-stimulated tubulin
polymerisation, and furthermore was a competitive inhibitor at the
colchicine-binding site of tubulin. Further evidence of STX2484
targeting microtubules can be seen from its marked effect on the
cellular microtubule structure.
It was also anticipated that STX2484 would induce apoptosis as
observed in cells treated with related compounds (Foster et al,
2008). The DNA profile obtained with propidium iodide showed
cells in G1, S and G2/M phases, with apoptotic and dead cells being
represented by a sub G0/G1 population. However, in order to be
seen in the sub-G1 area, a cell must have lost enough DNA to
appear there; so if cells enter apoptosis from the S or G2/M phase
of the cell cycle, they may not appear in the sub-G1 peak. This may
explain the small difference comparing the sub-G1 peak of
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Figure 3. Cell cycle and apoptosis. (A) Cell cycle arrest. Cells were exposed to STX2484 for 24 h before being trypsinised, fixed, treated with
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STX2484- and paclitaxel-treated MCF-7DOX cells. Cells may be
committed to die by apoptosis, but they have not lost enough DNA
to be seen in the sub-G1 population.
The accumulation of cyclin B1 provokes mitotic catastrophe
that induces apoptosis. In our case, the microtubule disruption
caused by STX2484 led to cell cycle arrest in the G2/M phase with
accumulation of cyclin B1 (24 h treatment). Cyclin B1 was then
degraded (48 h treatment), and it is the absence of Cdk1/cyclin B1
activity that induces apoptosis (48 h treatment) as shown
previously (Yuan et al, 2004). Further investigation revealed that
STX2484 induced p53 protein expression and the cleavage of
caspase-3. Moreover, as Cdk1/cyclinB1 can phosphorylate BCL2 to
inhibit apoptosis, we showed the absence of phospho-BCL2 after
48 h treatment, which is consistent with the loss of cyclin B1 signal.
This implies that tumour cells activate the intrinsic apoptosis
pathway, although more work needs to be undertaken to confirm
the nature and details of the apoptosis pathway induced by
STX2484.
In addition to inducing apoptosis, STX2484 is a potent anti-
angiogenic agent both in vitro and in vivo as shown by the lack of
vessel formation in the co-culture model and the Matrigel plug
assay. These two models are driven by different pro-angiogenic
growth factors; bFGF drives the in vivomodel and VEGF drives the
in vitro model; despite this STX2484 was efficacious in both
models. Inhibiting VEGF-stimulated angiogenesis alone by the use
of bevacizumab (Avastin) has yielded disappointing clinical results
to date (Normanno et al, 2009). This suggests there are multiple
pathways involved in stimulating angiogenesis, and agents such as
STX2484, which target more than one pathway, may have greater
clinical potency (Gaur et al, 2009; Korc and Friesel, 2009).
Many microtubule disrupters and other chemotherapeutic
agents have been investigated for potential anti-angiogenic activity
by the use of ‘metronomic’ dosing schedules. The rationale behind
this is that tumour-associated endothelial cells are sensitive to such
drugs as they rapidly divide, and the vasculature that they are part
of is immature and unstable (Kerbel and Kamen, 2004). However,
owing to the highly toxic nature of these compounds, the dose used
for regular metronomic dosing is far lower than the optimal
‘traditional’ intermittent anti-tumour dose. Although low-dose
regular administration of such agents may have anti-angiogenic
effects, the direct anti-tumour efficacy may be diminished. In this
study, STX2484 was dosed orally for 35 consecutive days at the
optimal anti-tumour dose (20mg kg 1), which inhibited growth
by 84% compared with control (at day 28) with no visible signs of
toxicity. Although we used paclitaxel-sensitive MDA-MB-231
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xenografts, this combination of regular oral dosing, anti-angiogenic
activity and direct anti-tumour efficacy bodes well for the future
development of STX2484 as a new generation cytotoxic agent.
Future comparison of STX2484 vs paclitaxel in paclitaxel-resistant
MCF-7DOX and MCF-7-TUBB3 xenografts will be critical to
support these findings. Future experiments will also investigate
STX2484’s safety profile and, as its structure is based on 2-MeOE2
and 2-methoxyoestradiol-3,17-O,O-bis-sulphamate, we anticipate
that STX2484 will have a similar acceptable toxicity profile with no
effect on plasma neutrophil concentrations (Meyer-Losic et al,
2013). Furthermore, as STX2484’s core structure is based on
2-MeOE2, we will also investigate this compound’s metabolism
in vitro and in vivo; 17b-hydroxysteroid dehydrogenase type-2
activity is known to inactivate 2-MeOE2 and, also with extensive
metabolic conjugation, is one of the main reasons for this
compound’s clinical failure and poor bioavailibility (Newman
et al, 2006). STX2484 possesses no free hydroxyl groups and
thus will not be a substrate for 17b-hydroxysteroid dehydrogenase
type-2 nor for conjugating enzymes, giving it a clear advantage.
One of the major problems facing current cytotoxic agents, such
as paclitaxel, is drug resistance, both intrinsic and acquired.
Although many mechanisms of drug resistance have been
described in vitro, such as tubulin point mutations, few have been
demonstrated in clinical specimens (Kelley et al, 2001; Orr et al,
2003; Fojo and Menefee, 2005). Two mechanisms, which have been
shown in the clinic, are the expression of a drug efflux pump,
P-glycoprotein, and the overexpression of the bIII tubulin isoform
(Burkhart et al, 2001; Orr et al, 2003). In this study, the efficacy of
STX2484 was unaffected by either overexpression of P-glycopro-
tein or bIII tubulin; in contrast, paclitaxel was significantly less
active in both models. If these data can be confirmed in future
in vivo PK-PD pre-clinical models and in the clinic, this would
potentially make STX2484 an extremely promising agent for the
treatment of breast cancer.
In summary, the results of this study demonstrate that STX2484
is a potent anti-proliferative agent, which is active in taxane-
resistant models of breast cancer. It acts as a microtubule-
disrupting agent arresting cells in the G2/M phase with subsequent
apoptosis. In addition, STX2484 is a potent inhibitor of angiogen-
esis both in vitro and in vivo. These activities, combined with
excellent solubility and regular oral dosing, are reflected in the
virtually complete inhibition of tumour growth in the MDA-MB-
231 breast cancer xenograft model in this study.
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